Is It Really SIFO? How Does It Differ from SIBO and How to Treat This Condition?

Small intestinal fungal overgrowth syndrome, abbreviated as SIFO (derived from *Small Intestinal Fungal Overgrowth*), represents a pathological condition marked by the uncontrolled proliferation of microscopic fungal organisms—primarily those of the *Candida* genus—within the lumen of the small intestine. While these microorganisms naturally colonize the gastrointestinal tracts of most individuals as part of the physiological microbiota, their excessive growth can precipitate digestive disturbances as well as systemic inflammatory responses. Under optimal conditions, the body’s immune defenses maintain these fungi in equilibrium with other microbial populations. However, factors such as compromised immune function, prolonged antibiotic use, impaired intestinal motility, or alterations in gut pH may facilitate their translocation from the large intestine to the small bowel, where they induce clinical manifestations resembling those observed in small intestinal bacterial overgrowth (SIBO) but with a distinct fungal etiology.

SIFO can be easily confused with SIBO, which is a small intestinal bacterial overgrowth. Both of these pathological conditions are associated with similar symptoms of mainly intestinal dysfunction but are caused by other types of microorganisms that overpopulate the intestine.

Historically, the primary predisposing conditions for small intestinal fungal overgrowth (SIFO) were considered to be states of compromised immune function associated with HIV infection, post-solid organ transplantation, immunosuppressive cancer treatments, or long-standing diabetes mellitus complicated by chronic hyperglycemia. Additionally, episodes of SIFO have been observed to emerge following broad-spectrum antibiotic regimens or prolonged corticosteroid administration. Vulnerable populations also include the elderly and pediatric patients, in whom the innate intestinal immune barrier may be inherently weakened. Epidemiological evidence further indicates an elevated prevalence of SIFO among hospitalized individuals compared to those managed in outpatient settings. Nevertheless, the etiopathogenesis of this condition in patients presenting with idiopathic gastrointestinal symptoms, as well as in immunocompetent individuals, remains incompletely elucidated. Contemporary scientific investigations have expanded the repertoire of potential risk factors, identifying proton pump inhibitor (PPI) therapy and small intestinal motility disorders as significant correlates of SIFO development, as substantiated in a 2013 study led by C. Jacobs and colleagues.

Individuals diagnosed with small intestinal fungal overgrowth (SIFO) routinely present with a constellation of gastrointestinal complaints, among which the most prevalent include recurrent abdominal discomfort or acute pain localized within the peritoneal cavity, excessive intestinal gas production resulting in pronounced abdominal distension, a subjective sensation of liquid or semisolid contents "sloshing" within the stomach or premature satiety immediately following meal ingestion, dyspeptic symptoms characterized by postprandial fullness or heaviness, frequent eructation of gastric air or regurgitation of stomach contents, intermittent episodes of nausea, and paroxysmal vomiting. Additionally, a substantial proportion of affected patients exhibit accelerated intestinal transit with concomitant diarrheal episodes, which may ultimately precipitate significant electrolyte imbalances and progressive systemic dehydration. Consequently, in cases of severe gastrointestinal symptomatology, the prompt initiation of symptomatic management is imperative to restore physiological stability. While the aforementioned clinical features are not pathognomonic for SIFO and may similarly manifest in numerous alternative gastrointestinal disorders, epidemiological evidence suggests that up to approximately 25% of patients with chronic intestinal complaints may have underlying small intestinal fungal overgrowth as the primary etiologic factor.

At present, the most reliable diagnostic approach for confirming or ruling out small intestinal fungal overgrowth (SIFO) involves the endoscopic retrieval of luminal contents—specifically from the duodenal region or the proximal jejunum—during either gastroscopy or enteroscopy. The obtained biological specimen is then subjected to comprehensive microbiological cultivation to identify fungal colonies, with particular emphasis on *Candida* species. It is important to note that *Candida* cells may also be detected in fecal samples at concentrations ranging from 10² to 10³ CFU/mL; however, this does not necessarily indicate an active infection, as these organisms often represent commensal flora naturally inhabiting the gastrointestinal tract without causing pathology, provided the host’s immune system remains competent. In immunocompromised individuals, however, microscopic examination of stool samples may reveal an abnormally elevated *Candida* burden, serving as a critical diagnostic indicator. No universally standardized threshold (*cut-off value*) exists to distinguish physiological colonization from pathological overgrowth; clinical practice nonetheless suggests that detection of more than 10³ fungal cells per milliliter of small intestinal content may support a SIFO diagnosis. Additionally, when evaluating concurrent small intestinal bacterial overgrowth (SIBO), diagnostic protocols may include both bacterial culture of intestinal aspirates and—far more commonly—hydrogen-methane breath testing, which measures exhaled gas concentrations to assess microbial fermentation activity.

The clinical approach to managing small intestinal fungal overgrowth (SIFO) is contingent upon the patient’s individualized health profile, encompassing their overall medical condition, prior therapeutic interventions, and the progression of comorbid diseases. To achieve complete eradication of the pathogenic fungal organism, a structured treatment regimen lasting a minimum of two to three weeks—based on antifungal pharmaceutical agents—is deemed essential. Pharmacological interventions incorporate active compounds from distinct drug classes, including azole derivatives, echinocandin-class medications, and polyene antibiotics. It is important to emphasize that while these treatment protocols frequently yield symptomatic relief characteristic of SIFO, their efficacy cannot be universally assured across all clinical scenarios. By contrast, the management of small intestinal bacterial overgrowth (SIBO) conventionally relies on broad-spectrum antibiotics or eubiotics such as rifaximin, which selectively alters microbial composition without systemic absorption into the bloodstream.

Even following successful treatment, small intestinal fungal overgrowth (SIFO) is prone to recurrence, underscoring the necessity of implementing targeted nutritional strategies to sustain intestinal microbial equilibrium. The foundational and non-negotiable principle in both the therapeutic management and prevention of SIFO remains the stringent restriction of simple carbohydrate intake, including sucrose, fructose, and glucose. Individuals diagnosed with this condition must entirely eliminate high-sugar foods from their diet, such as confectionery, sweetened dairy products, carbonated beverages, and fruit juices with added sugars. However, a measured consumption of low-glycemic fruits—limited to one daily serving (e.g., berries or green apples)—is permissible, provided there is no adverse gastrointestinal reaction. During periods of active dyspeptic symptoms (e.g., bloating, abdominal pain, or diarrhea), a temporary exclusion of fermentable, indigestible, or high-fiber foods is advised, including whole-grain products, legumes, nuts, cruciferous vegetables (e.g., cabbage, broccoli), and edible fungi. Upon resolution of gastrointestinal distress, the diet should be gradually reintroduced to these previously restricted items due to their beneficial role in fostering microbial diversity within the gut. While probiotic supplementation and fecal microbiota transplantation are not currently standardized interventions for SIFO, ongoing clinical trials continue to evaluate their potential efficacy as adjunctive therapies.

Small intestinal fungal overgrowth represents a relatively recently characterized gastrointestinal pathology. While its clinical presentation may closely mirror that of small intestinal bacterial overgrowth (SIBO), the diagnostic methodologies and therapeutic interventions exhibit substantial divergences. In the context of investigating functional gastrointestinal disturbances, it is imperative to consider both conditions as potential etiologic factors, thereby facilitating accurate diagnosis and the implementation of an evidence-based treatment regimen.